Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CA 2310630 A1 · Owner: Allergan Sales, Llc · Inventors: Burk, Robert M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The compounds used in accordance with the invention are represented by formula (I), wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration; the solid triangle is used to indicate .beta. configuration; dashed bonds represent a double bond or a single bond; R is a , substituted heteroaryl radical having at least two pendant substituents selected from the group consisting of C1 to C6 alkyl; halogen; trifluoromethyl; COR1; COCF3; SO2NR1; NO2 and CN or at least one cyano group; R1 is hydrogen or a lower …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 17, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.